Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment

被引：22

作者：

Koyama T. ^{[1
]}

Nimura H. ^{[1
]}

Kobayashi K. ^{[1
]}

Marushima H. ^{[1
]}

Odaira H. ^{[1
]}

Kashimura H. ^{[1
]}

Mitsumori N. ^{[1
]}

Yanaga K. ^{[1
]}

机构：

[1] Department of Surgery, Jikei University, School of Medicine, Minato-ku, Tokyo 105-8461

来源：

Gastric Cancer | 2006年 / 9卷 / 3期

关键词：

c-kit; Gastrointestinal stromal tumor; Imatinib; Mutation; Resistance;

D O I：

10.1007/s10120-006-0368-5

中图分类号：

学科分类号：

摘要：

A 57-year-old man with gastrointestinal stromal tumor (GIST) of the stomach with peritoneal dissemination underwent gastrectomy. After surgery, he was treated with 400 mg/day of imatinib, without recurrence, for 26 months. At 26 months, the imatinib dose was reduced because of nausea, and 4 months after the dose reduction, recurrence of GIST was detected, for which surgical resection was performed again. The first surgical specimen had a mutation of exon 11 in the c-kit receptor gene. Intriguingly, the second surgical specimen had a novel mutation of exon 17, in addition to the above-mentioned mutation, in the c-kit receptor gene. Based on the result of molecular analysis, the novel mutation of exon 17, induced by longterm chemotherapy, was judged to have been responsible for the recurrence, which perhaps was triggered by the dose reduction of imatinib. © 2006 by International and Japanese Gastric Cancer Associations.

引用

页码：235 / 239

页数：4

共 13 条

[1] Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Et al., Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors, Science, 279, pp. 577-80, (1998)
[2] Ma Y., Zeng S., Metcalfe D.D., Akin C., Dimitrijevic S., Butterfield J.H., Et al., The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors: Kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations, Blood, 99, pp. 1741-4, (2002)
[3] Debiec-Rychter M., Cools J., Dumez H., Sciot R., Stul M., Mentens N., Et al., Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants, Gastroenterology, 128, pp. 270-9, (2005)
[4] Tamborini E., Bonadiman L., Greco A., Albertini V., Negri T., Gronchi A., Et al., A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient, Gastroenterology, 127, pp. 294-9, (2004)
[5] Hirota S., Ohashi A., Nishida T., Isozaki K., Kinoshita K., Shinomura Y., Et al., Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors, Gastroenterology, 125, pp. 660-7, (2003)
[6] Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., Zigler A.J., Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor, Blood, 96, pp. 925-32, (2000)
[7] Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Et al., Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat Med, 2, pp. 561-6, (1996)
[8] Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., Et al., Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor, N Engl J Med, 344, pp. 1052-6, (2001)
[9] Van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato Di Paola E., Dimitrijevic S., Et al., Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study, Lancet, 358, pp. 1421-3, (2001)
[10] Verweij J., Casali P.G., Zalcberg J., Lecesne A., Reichardt P., Blay J.Y., Et al., Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial, Lancet, 364, pp. 1127-34, (2004)

← 1 2 →